240 related articles for article (PubMed ID: 31937834)
41. Conformational Transition of Key Structural Features Involved in Activation of ALK Induced by Two Neuroblastoma Mutations and ATP Binding: Insight from Accelerated Molecular Dynamics Simulations.
He MY; Li WK; Zheng QC; Zhang HX
ACS Chem Neurosci; 2018 Jul; 9(7):1783-1792. PubMed ID: 29638111
[TBL] [Abstract][Full Text] [Related]
42. Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.
Siaw JT; Wan H; Pfeifer K; Rivera VM; Guan J; Palmer RH; Hallberg B
Oncotarget; 2016 May; 7(20):29011-22. PubMed ID: 27049722
[TBL] [Abstract][Full Text] [Related]
43. Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma.
Emdal KB; Pedersen AK; Bekker-Jensen DB; Lundby A; Claeys S; De Preter K; Speleman F; Francavilla C; Olsen JV
Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459283
[TBL] [Abstract][Full Text] [Related]
44. Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment.
Javanmardi N; Fransson S; Djos A; Sjöberg RM; Nilsson S; Truvé K; Kogner P; Martinsson T
Sci Rep; 2019 Feb; 9(1):2199. PubMed ID: 30778092
[TBL] [Abstract][Full Text] [Related]
45. 11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma.
Siaw JT; Javanmardi N; Van den Eynden J; Lind DE; Fransson S; Martinez-Monleon A; Djos A; Sjöberg RM; Östensson M; Carén H; Trøen G; Beiske K; Berbegall AP; Noguera R; Lai WY; Kogner P; Palmer RH; Hallberg B; Martinsson T
Cell Rep; 2020 Sep; 32(12):108171. PubMed ID: 32966799
[TBL] [Abstract][Full Text] [Related]
46. Frequency of ALK and GD2 Expression in Neuroblastoma.
Aygün Z; Batur Ş; Emre Ş; Celkan T; Özman O; Comunoglu N
Fetal Pediatr Pathol; 2019 Aug; 38(4):326-334. PubMed ID: 30955398
[No Abstract] [Full Text] [Related]
47. Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations.
Brady SW; Liu Y; Ma X; Gout AM; Hagiwara K; Zhou X; Wang J; Macias M; Chen X; Easton J; Mulder HL; Rusch M; Wang L; Nakitandwe J; Lei S; Davis EM; Naranjo A; Cheng C; Maris JM; Downing JR; Cheung NV; Hogarty MD; Dyer MA; Zhang J
Nat Commun; 2020 Oct; 11(1):5183. PubMed ID: 33056981
[TBL] [Abstract][Full Text] [Related]
48. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours.
Carén H; Abel F; Kogner P; Martinsson T
Biochem J; 2008 Dec; 416(2):153-9. PubMed ID: 18990089
[TBL] [Abstract][Full Text] [Related]
49. Direct Targeting of
Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H
Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073
[TBL] [Abstract][Full Text] [Related]
50. Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.
Torossian A; Broin N; Frentzel J; Daugrois C; Gandarillas S; Saati TA; Lamant L; Brousset P; Giuriato S; Espinos E
Haematologica; 2019 Jul; 104(7):1428-1439. PubMed ID: 30679328
[TBL] [Abstract][Full Text] [Related]
51. The prognostic roles of and correlation between
Chang HH; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Hsu WM; Jeng YM; Jou ST
J Clin Pathol; 2020 Mar; 73(3):154-161. PubMed ID: 31542727
[TBL] [Abstract][Full Text] [Related]
52. ETV5 transcription program links BDNF and promotion of EMT at invasive front of endometrial carcinomas.
Alonso-Alconada L; Eritja N; Muinelo-Romay L; Barbazan J; Lopez-Lopez R; Matias-Guiu X; Gil-Moreno A; Dolcet X; Abal M
Carcinogenesis; 2014 Dec; 35(12):2679-86. PubMed ID: 25233929
[TBL] [Abstract][Full Text] [Related]
53. Long Noncoding RNA pancEts-1 Promotes Neuroblastoma Progression through hnRNPK-Mediated β-Catenin Stabilization.
Li D; Wang X; Mei H; Fang E; Ye L; Song H; Yang F; Li H; Huang K; Zheng L; Tong Q
Cancer Res; 2018 Mar; 78(5):1169-1183. PubMed ID: 29311158
[TBL] [Abstract][Full Text] [Related]
54. ETS variant 5 promotes colorectal cancer angiogenesis by targeting platelet-derived growth factor BB.
Cheng X; Jin Z; Ji X; Shen X; Feng H; Morgenlander W; Ou B; Wu H; Gao H; Ye F; Zhang Y; Peng Y; Liang J; Jiang Y; Zhang T; Qiu W; Lu X; Zhao R
Int J Cancer; 2019 Jul; 145(1):179-191. PubMed ID: 30650178
[TBL] [Abstract][Full Text] [Related]
55. The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
Infarinato NR; Park JH; Krytska K; Ryles HT; Sano R; Szigety KM; Li Y; Zou HY; Lee NV; Smeal T; Lemmon MA; Mossé YP
Cancer Discov; 2016 Jan; 6(1):96-107. PubMed ID: 26554404
[TBL] [Abstract][Full Text] [Related]
56. Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.
Berlak M; Tucker E; Dorel M; Winkler A; McGearey A; Rodriguez-Fos E; da Costa BM; Barker K; Fyle E; Calton E; Eising S; Ober K; Hughes D; Koutroumanidou E; Carter P; Stankunaite R; Proszek P; Jain N; Rosswog C; Dorado-Garcia H; Molenaar JJ; Hubank M; Barone G; Anderson J; Lang P; Deubzer HE; Künkele A; Fischer M; Eggert A; Kloft C; Henssen AG; Boettcher M; Hertwig F; Blüthgen N; Chesler L; Schulte JH
Mol Cancer; 2022 Jun; 21(1):126. PubMed ID: 35689207
[TBL] [Abstract][Full Text] [Related]
57. PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma.
Bachetti T; Di Paolo D; Di Lascio S; Mirisola V; Brignole C; Bellotti M; Caffa I; Ferraris C; Fiore M; Fornasari D; Chiarle R; Borghini S; Pfeffer U; Ponzoni M; Ceccherini I; Perri P
PLoS One; 2010 Oct; 5(10):. PubMed ID: 20957039
[TBL] [Abstract][Full Text] [Related]
58. Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.
Fransson S; Hansson M; Ruuth K; Djos A; Berbegall A; Javanmardi N; Abrahamsson J; Palmer RH; Noguera R; Hallberg B; Kogner P; Martinsson T
Genes Chromosomes Cancer; 2015 Feb; 54(2):99-109. PubMed ID: 25251827
[TBL] [Abstract][Full Text] [Related]
59. Identification of ALK as a major familial neuroblastoma predisposition gene.
Mossé YP; Laudenslager M; Longo L; Cole KA; Wood A; Attiyeh EF; Laquaglia MJ; Sennett R; Lynch JE; Perri P; Laureys G; Speleman F; Kim C; Hou C; Hakonarson H; Torkamani A; Schork NJ; Brodeur GM; Tonini GP; Rappaport E; Devoto M; Maris JM
Nature; 2008 Oct; 455(7215):930-5. PubMed ID: 18724359
[TBL] [Abstract][Full Text] [Related]
60. Novel adaptor protein Shf interacts with ALK receptor and negatively regulates its downstream signals in neuroblastoma.
Takagi D; Tatsumi Y; Yokochi T; Takatori A; Ohira M; Kamijo T; Kondo S; Fujii Y; Nakagawara A
Cancer Sci; 2013 May; 104(5):563-72. PubMed ID: 23360421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]